Oncolytics Biotech (TSE:ONC) has released an update.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Oncolytics Biotech is set to showcase promising results of their immunotherapy drug, pelareorep, in treating hard-to-treat gastrointestinal cancers at the upcoming ASCO GI Symposium. The data highlights pelareorep’s ability to enhance the effectiveness of existing cancer treatments, potentially improving patient outcomes in pancreatic and anal cancers.
For further insights into TSE:ONC stock, check out TipRanks’ Stock Analysis page.